Related Experiment Video
Updated: Aug 13, 2026

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
[Novel perspectives of COPD pharmacotherapy: focus on neutrophils]
Abstract:
Inflammation in COPD is characterized by an increased presence and activation of airway neutrophils. However, since currently available treatment options have only limited effects on neutrophilic airway inflammation, great efforts are undertaken to develop novel therapies targeting the neutrophilic component of inflammation in COPD. The present review discusses the rationale for anti-neutrophilic treatment in COPD and provides a critical overview of recent developments in drug therapy. Moreover, open questions and limitations of clinical trials including choice of adequate outcome parameters for proof-of-concept studies with putative anti-neutrophilic drugs and potential safety issues are summarized.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation